跳轉至內容
Merck
全部照片(1)

Key Documents

Q0100000

Quinidine sulfate

European Pharmacopoeia (EP) Reference Standard

同義詞:

Quinidine sulfate salt dihydrate

登入查看組織和合約定價


About This Item

經驗公式(希爾表示法):
C40H48N4O4 · H2O4S · 2H2O
CAS號碼:
分子量::
782.94
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

quinidine

製造商/商標名

EDQM

mp

212-214 °C (dec.) (lit.)

應用

pharmaceutical (small molecule)

格式

neat

儲存溫度

2-8°C

SMILES 字串

[H]O[H].[H]O[H].OS(O)(=O)=O.[H][C@]1(CN2CCC1C[C@]2([H])[C@@H](O)c3ccnc4ccc(OC)cc34)C=C.[H][C@]5(CN6CCC5C[C@]6([H])[C@@H](O)c7ccnc8ccc(OC)cc78)C=C

InChI

1S/2C20H24N2O2.H2O4S.2H2O/c2*1-3-13-12-22-9-7-14(13)10-19(22)20(23)16-6-8-21-18-5-4-15(24-2)11-17(16)18;1-5(2,3)4;;/h2*3-6,8,11,13-14,19-20,23H,1,7,9-10,12H2,2H3;(H2,1,2,3,4);2*1H2/t2*13-,14?,19-,20+;;;/m11.../s1

InChI 密鑰

ZHNFLHYOFXQIOW-WFTMRWCJSA-N

尋找類似的產品? 前往 產品比較指南

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Quinidine sulfate EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

生化/生理作用

IA 类抗心律失常药;钾通道阻断剂。

包裝

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他說明

Sales restrictions may apply.

象形圖

Exclamation mark

訊號詞

Warning

危險聲明

防範說明

危險分類

Acute Tox. 4 Oral

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 1

閃點(°F)

Not applicable

閃點(°C)

Not applicable


從最近期的版本中選擇一個:

分析證明 (COA)

Lot/Batch Number

抱歉,我們目前沒有在線上提供本產品的COA

如果您需要協助,請聯絡 客戶支援

已經擁有該產品?

您可以在文件庫中找到最近購買的產品相關文件。

存取文件庫

客戶也查看了

Slide 1 of 1

1 of 1

Motoya Suzuki et al.
Xenobiotica; the fate of foreign compounds in biological systems, 44(11), 1039-1045 (2014-05-21)
1.  This study was aimed to characterize gastrointestinal absorption of digoxin using wild-type (WT) and multidrug resistance protein 1a [mdr1a; P-glycoprotein (P-gp)] knockout (-/-) rats. 2.  In WT rats, the area under the plasma concentration-time curve (AUC) of oral digoxin
Yuki Ogawa et al.
European journal of pediatrics, 174(4), 509-518 (2014-09-25)
This study aimed to determine the population pharmacokinetics of doxapram in low-birth-weight (LBW) infants. A total of 92 serum concentration measurements that were obtained from 34 Japanese neonates were analyzed using nonlinear mixed-effect modeling (NONMEM). Estimates generated by NONMEM indicated
Maria Addolorata Saracino et al.
Journal of pharmaceutical and biomedical analysis, 95, 61-67 (2014-03-19)
A rapid and reliable analytical method has been developed to quantify the melatonergic antidepressant agomelatine in three matrices, and namely saliva, plasma and dried blood spots. The method is based on the use of liquid chromatography with fluorimetric detection exploiting
Mikiko Tsukimoto et al.
Biopharmaceutics & drug disposition, 36(1), 15-33 (2014-09-30)
Aliskiren is a substrate for P-glycoprotein (P-gp) and is metabolized via cytochrome P450 3A4 (CYP3A4). The aim of the present study was to assess whether P-gp influenced the pharmacokinetics of aliskiren and also if drug-drug interactions (DDIs) mediated through P-gp
Laura Kervezee et al.
The AAPS journal, 16(5), 1029-1037 (2014-06-12)
Nearly all bodily processes exhibit circadian rhythmicity. As a consequence, the pharmacokinetic and pharmacodynamic properties of a drug may also vary with time of day. The objective of this study was to investigate diurnal variation in processes that regulate drug

條款

LC/MS/MS Analysis of Drugs in Plasma on Ascentis® Express C18 after Extraction using SPME LC Tips

我們的科學家團隊在所有研究領域都有豐富的經驗,包括生命科學、材料科學、化學合成、色譜、分析等.

聯絡技術服務